FDA's first AI-misuse warning letter wasn’t so much about AI
Purolea Cosmetics Lab's FDA warning letter made headlines as the first to cite AI misuse in manufacturing. But strip away the AI angle and the real story is a quality unit that had already collapsed. Part 3 closes a series on why AI regulation isn't leveling the playing field — yet.
PFAS: wait-and-see Vs precautionary principle
When data is limited, do you default to safety or wait for proof of harm? This post explores the widening regulatory gap between the US and EU regarding PFAS - the "Forever Chemicals."
FDA’s new guidance on general wellness
This post critiques the widening regulatory gap between the US and EU following the FDA's new wellness guidance, highlighting how lower barriers for bold health claims in the US may sacrifice essential quality drivers and complicate global strategies for startups.
